| 2023年年报 | 2022年年报 | 2022年一季报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CDMO业务(元) | - | - | 10,538,365.33 |
| 仿制药(元) | 20,550,654.86 | 9,961,138.84 | 513,401.06 |
| 医药技术服务(元) | 6,120,655.16 | 5,010,773.60 | - |
| 中间体及原料药(元) | 98,093,642.39 | 75,024,065.57 | - |
| 营业成本(元) | |||
| CDMO业务(元) | - | - | 13,632,387.88 |
| 仿制药(元) | 13,963,709.31 | 7,336,010.58 | 94,339.62 |
| 医药技术服务(元) | 2,740,594.24 | 3,674,242.24 | - |
| 中间体及原料药(元) | 75,730,786.02 | 75,965,699.40 | - |
| 毛利(元) | |||
| CDMO业务(元) | - | - | -3,094,022.55 |
| 仿制药(元) | 6,586,945.55 | 2,625,128.26 | 419,061.44 |
| 医药技术服务(元) | 3,380,060.92 | 1,336,531.36 | - |
| 中间体及原料药(元) | 22,362,856.37 | -941,633.83 | - |
| 毛利率(%) | |||
| CDMO业务(%) | - | - | -29.36 |
| 仿制药(%) | 32.05 | 26.35 | 81.62 |
| 医药技术服务(%) | 55.22 | 26.67 | - |
| 中间体及原料药(%) | 22.80 | -1.26 | - |
| 收入构成(%) | |||
| CDMO业务(%) | - | - | 95.35 |
| 仿制药(%) | 16.47 | 11.07 | 4.65 |
| 医药技术服务(%) | 4.91 | 5.57 | - |
| 中间体及原料药(%) | 78.62 | 83.36 | - |
| 毛利构成(%) | |||
| CDMO业务(%) | - | - | - |
| 仿制药(%) | 20.37 | 86.92 | - |
| 医药技术服务(%) | 10.45 | 44.26 | - |
| 中间体及原料药(%) | 69.17 | -31.18 | - |